Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Cadonilimab + Chemo for Stage IB2 Cervical Cancer
NCT06289751Phase 2Recruiting
- Sponsor
- Tongji Hospital
- Start
- Sep 2024
- Primary completion
- Mar 2026
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in Cervical Cancer (CC), sponsored by Tongji Hospital. Started Sep 2024; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06289751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06289751.